Suppr超能文献

凝血酶原片段1+2(F 1+2)随口服抗凝强度增加的变化——关于F 1+2用于监测口服抗凝治疗适用性的思考

Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment.

作者信息

Tripodi A, Cattaneo M, Molteni A, Cesana B M, Mannucci P M

机构信息

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, University and IRCCS Maggiore Hospital, Milano, Italy.

出版信息

Thromb Haemost. 1998 Mar;79(3):571-3.

PMID:9531043
Abstract

Plasma F 1+2 levels, the activation peptide originating from the factor Xa-mediated activation of prothrombin, increase in many clinical conditions associated with hypercoagulability and decrease in patients on oral anticoagulant treatment (OAT). However. the usefulness of F 1+2 measurement to monitor OAT has not yet been investigated in clinical studies. Before those studies are attempted, the plausibility of its implementation in the laboratory control of OAT should be evaluated. In this respect, a thorough investigation of the pattern of changes of F 1+2 as a function of increased intensity of anticoagulation expressed as International Normalized Ratio is essential. One hundred and thirty-two patients on long-term warfarin treatment were recruited to cover 8 ranges of anticoagulation from < 1.5 to 9.0 INR. F 1+2 was measured in batch on frozen plasma and INR was determined on fresh plasma. The relationship of F 1+2 vs. INR showed a hyperbolic pattern with F 1+2 levels decreasing progressively and significantly as a function of increasing INR up to 3.0. A further decrease in F 1+2 levels observed at INR up to 4.0 was not statistically significant. At INR greater than 4.0, F 1+2 reached a plateau, with mean levels not significantly different for patients at increasing INR up to 9.0. Since the risk of bleeding increases at INR greater than 4.5, our results suggest that F 1+2 is of little value to assess the hemorrhagic risk in patients on OAT.

摘要

血浆F 1+2水平是由凝血因子Xa介导的凝血酶原激活产生的激活肽,在许多与高凝状态相关的临床情况下会升高,而在接受口服抗凝治疗(OAT)的患者中则会降低。然而,F 1+2检测用于监测OAT的有效性尚未在临床研究中得到探讨。在尝试进行这些研究之前,应评估其在OAT实验室控制中的可行性。在这方面,全面研究F 1+2随以国际标准化比值表示的抗凝强度增加而变化的模式至关重要。招募了132名接受长期华法林治疗的患者,以涵盖从<1.5至9.0国际标准化比值的8个抗凝范围。对冷冻血浆批量检测F 1+2,并在新鲜血浆上测定国际标准化比值。F 1+2与国际标准化比值的关系呈双曲线模式,随着国际标准化比值增加至3.0,F 1+2水平逐渐且显著下降。在国际标准化比值高达4.0时观察到的F 1+2水平进一步下降无统计学意义。在国际标准化比值大于4.0时,F 1+2达到平台期,对于国际标准化比值增加至9.0的患者,平均水平无显著差异。由于国际标准化比值大于4.5时出血风险增加,我们的结果表明,F 1+2在评估接受OAT患者的出血风险方面价值不大。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验